Gyre Therapeutics, Inc.
Income Statement
| Line Item | FY2010 | FY2009 |
|---|---|---|
| Revenue | $85.7M | $25.1M |
| Cost of Revenue | — | $691.0K |
| Gross Profit | — | $24.4M |
| Gross Margin | — | 97.2% |
| Operating Expenses | ||
| Research & Development | $64.5M | $40.2M |
| SG&A Expense | $8.1M | $8.2M |
| Operating Income | $13.1M | $-40.3M |
| Operating Margin | 15.3% | -160.9% |
| Interest Expense | $153.0K | $217.0K |
| Pretax Income | $14.4M | $-39.5M |
| Income Tax Expense | $3.5M | $-88.0K |
| Net Income | $10.9M | $-39.4M |
| Net Margin | 12.7% | -157.2% |
| EPS (Basic) | $0.19 | $-0.77 |
| EPS (Diluted) | $0.18 | $-0.77 |
| Shares Outstanding (Basic) | 57.1M | 51.3M |
| Shares Outstanding (Diluted) | 60.3M | 51.3M |
| Dividends Per Share | — | — |